dr. angela el-adas director-general, ghana aids commission
DESCRIPTION
Abstract no. FRAE0103. Economic Evaluation of the National Program to Prevent Mother-to-Child Transmission of HIV in Ghana. Dr. Angela El-Adas Director-General, Ghana AIDS Commission. Study Team. Ghana AIDS Commission A. El-Adas R . Amenyah K. Atuahene - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/1.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Economic Evaluation of the National Program to Prevent
Mother-to-Child Transmission of HIV in Ghana
Dr. Angela El-Adas
Director-General, Ghana AIDS Commission
Abstract no. FRAE0103
![Page 2: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/2.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Study Team• Ghana AIDS Commission
– A. El-Adas– R. Amenyah – K. Atuahene
• Futures Group, Health Policy Project– A. Koleros
• Ghana Health Service, National AIDS and STI Control Program– N. Akwei Addo– K. Asante
• University of Ghana, Institute of Statistical, Social, and Economic Research– F. Asante
• USAID Ghana– P. Wondergem
![Page 3: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/3.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Background
• Government of Ghana introduced new National PMTCT Guidelines in 2010– New World Health Organization (WHO) clinical
guidelines – New antiretroviral (ARV) drug regimens – Clinical services as part of routine care for PMTCT
clients
• No studies in Ghana had examined the cost of delivering these services
• Few international studies have examined costs of PMTCT services under new WHO guidelines
![Page 4: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/4.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
• What is the cost of providing PMTCT services for one woman and child from pregnancy through the recommended period of postpartum care according to national guidelines?
– Cost of providing PMTCT services to an HIV-negative woman?
– Cost of providing PMTCT services to an HIV-positive woman?– Cost of providing PMTCT services to an HIV-exposed infant?
Study questions
![Page 5: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/5.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Methodology• Used mixed methods
o Document reviewo Key informant interviews
• Analyzed the cost of main facility-based PMTCT services under new PMTCT guidelines o HIV testing and counseling (HTC)o Antiretroviral prophylaxis and/or therapy for sero-positive pregnant women
and postpartum care for sero-positive mothers and their HIV-exposed infants
• Developed a representative care schedule o Based on national guidelineso Refined during interviews
• Collected data at the central level and from a purposive sample of 14 facilities reflecting characteristics thought to influence unit cost, including facility level and facility ownership
![Page 6: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/6.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Definition of PMTCT• The cost of providing PMTCT services to one woman
from intake in the PMTCT program during the 1st trimester through the recommended period of postpartum care
• The cost of providing PMTCT services to one HIV-exposed infant from delivery through the recommended period of postpartum care
• Total period of 21 months– 9 months of pregnancy– 12 months of breastfeeding
![Page 7: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/7.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Key Results
![Page 8: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/8.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Unit cost for Mother/Child pairs (USD)
Mother: Sero-negative
Mother: ARV Prophylaxis / HIV-exposed infant (6 wks)
Mother: ARV Prophylaxis / HIV-exposed infant (6 mo.)
Mother: ARV Prophylaxis / HIV-exposed
infant (12 mo.)
Mother: ARV Treatment / HIV-exposed infant (6 wks)
Mother: ARV Treatment / HIV-exposed infant (6 mo.)
Mother: ARV Treatment / HIV-exposed
infant (12 mo.)
$-
$200
$400
$600
$800
$1,000
$1,200
$56
$739 $739 $739
$1,054 $1,054 $1,054
$29 $50 $69
$29 $50 $69 Mother Cost Infant Cost
![Page 9: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/9.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Distribution of Costfor Mother-Child Pairs
Mother: ARV Prophylaxis / HIV-exposed
infant (6 wks)
Mother: ARV Prophylaxis / HIV-exposed
infant (6 mo.)
Mother: ARV Prophylaxis / HIV-exposed
infant (12 mo.)
Mother: ARV Treatment /
HIV-exposed infant (6
wks)
Mother: ARV Treatment /
HIV-exposed infant (6
mo.)
Mother: ARV Treatment /
HIV-exposed infant (12
mo.)
96% 94% 91% 97% 95% 94%
4% 6% 9% 3% 5% 6%
Mother Cost Infant Cost
![Page 10: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/10.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Distribution of Direct and Indirect Costs, by Mother/Child
Pairs
Mother: Sero-negative
Mother: ARV Prophylaxis / HIV-exposed infant (6 wks)
Mother: ARV Prophylaxis / HIV-exposed infant (6 mo.)
Mother: ARV Prophylaxis / HIV-exposed
infant (12 mo.)
Mother: ARV Treatment / HIV-exposed infant (6 wks)
Mother: ARV Treatment / HIV-exposed infant (6 mo.)
Mother: ARV Treatment / HIV-exposed
infant (12 mo.)
100.000%
75.831% 76.467% 77.005% 82.856% 83.179% 83.456%
13.710% 13.350% 13.044%9.725% 9.542% 9.385%
10.459% 10.184% 9.951% 7.419% 7.279% 7.159%
Direct Cost Indirect Facility Costs General Program Supprt
![Page 11: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/11.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
• ARVs and associated lab tests constituted the largest cost components of both direct costs and overall costs.
• The data suggest that the unit cost of delivering PMTCT services will not vary significantly over time unless cost of ARVs are driven down
PMTCT Costs are Driven by Direct Costs
![Page 12: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/12.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
• Staff time was also a relatively large contributor to overall costs.
• Higher staff costs were associated with higher-level facilities.
• Further task shifting within PMTCT could achieve some cost savings in the long term. – Requires investments in training and building capacity
to ensure that the quality of service delivery is maintained.
Task Shifting
![Page 13: Dr. Angela El-Adas Director-General, Ghana AIDS Commission](https://reader036.vdocuments.site/reader036/viewer/2022062422/568132cd550346895d99919d/html5/thumbnails/13.jpg)
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Conclusions
• The study provided insight into – What is driving PMTCT costs– What can be done to achieve cost efficiencies
• These data can be used to better inform resource allocation decisions as PMTCT programs are scaled up across Ghana and other countries.